Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Malignant Mesothelioma
NCT00107432Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2004
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in malignant mesothelioma, sponsored by National Cancer Institute. Started Oct 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00107432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107432.